C20 C19 C18
Conditions
Interventions
Group 1: Patients treated in this study receive a local Therapy (Thermal ablation, Brachytherapy, Mikrowaveablation, stereotactical radiation, surgical resection) after there has been a progress while
Sponsors
Klinikum der Universität München, Campus Großhadern
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. histologically proven oligometastatic colorectal cancer (Oligometastatic disease status defined as involving up to 3 organ systems; up to 3 metastases per organ system) 2. Any treatment line irrespective of previous chemotherapy lines 3.Patient treatment recommendation confirmed by an institutional multidisciplinary tumor board (MDT) 4.Metastases amenable to complete ablation/resection using different techniques (radiofrequency ablation, thermoablation, photon beam radiation, surgery, including minimal invasive resections) 5.Age >18 Jahre 6.Life expectancy > 12 months 7. signed and dated consent form
Exclusion criteria
Exclusion criteria: 1. Patients with metastases involving more than 3 organ systems (e.g. liver, lung, bone and retroperitoneal compartment) 2. Patients with peritoneal or pleural metastases 3. Patient having undergone Whipple Operation 4. Second carcinoma, except carcinoma in situ of the cervix or basal cell carcinoma. 5. Pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| There is a proportionality between the fall of the free-circulating tumor DNA 8 weeks after therapy and 16-72 week interval and the progression free survival and / or overall survival. (Check of the degree of response) | — |
Secondary
| Measure | Time frame |
|---|---|
| Is tumor recurrence (Progression free survival) associated with a different profile of genetic alterations? | — |
Countries
Germany
Contacts
Public ContactChristel Besseler
Klinik und Poliklinik für Radiologie Klinikum der Universität München Campus Großhadern
Outcome results
None listed